Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

Thymosin Alpha-1: what it is studied alongside

Thymosin Alpha-1 is a thymus-derived peptide studied as a non-canonical HCRTR1 ligand in neuroprotection and as an immunomodulator alongside checkpoint inhibitors, chemotherapy and vaccine regimens.

peptides-pro Editorial

Thymosin Alpha-1 (Tα1), also written thymalfasin and thymosin α-1, is a thymus-derived peptide hormone of the immunomodulatory class. The evidence block used for this page does not supply a sequence, molecular formula or molecular weight for the compound, so none is stated here. In the literature cited below it is described as an endogenous thymus-derived peptide and as a peptide hormone produced by the thymus [1][3].

The mechanistic work summarised here centres on engagement of the Hypocretin (Orexin) Receptor 1 (HCRTR1), a classical neuropeptide receptor on neurons, by Thymosin Alpha-1 acting as a non-canonical ligand [1].

Research Studies

Thymosin Alpha-1 and HCRTR1 engagement in neuronal necroptosis models

Work on the thymus-to-CNS axis reported that Tα1 functions as a non-canonical ligand for HCRTR1 and that this engagement shields neurons from cell death by suppressing the activity of Receptor-Interacting Protein Kinase 3 (RIPK3), described in that paper as a central executioner of necroptosis [1]. The finding is framed as a direct neuroprotective axis linking the thymus to the central nervous system, and the authors state that the physiological relevance of the pathway is highlighted in their work [1]. This is mechanistic and preclinical in character; the evidence block does not report a human trial of Tα1 for neuronal necroptosis.

Thymosin Alpha-1 and immune-related adverse events secondary to checkpoint inhibitors

A case report described a patient with nasopharyngeal carcinoma who developed multisystem immune-related adverse events (irAEs) after treatment with the PD-1 inhibitor sintilimab in combination with thymosin alpha-1. The presentation included high fever, rash, interstitial pulmonary edema and multiple organ failure. The authors analysed the treatment course and regression and discussed risks and management strategies for combining immune checkpoint inhibitors with immunomodulators, concluding that clinical vigilance is needed against possible immune overactivation triggered by combination therapy [2].

A registered trial takes the opposite direction of enquiry, asking whether Tα-1 could be used as a therapeutic option for the treatment of immune-related adverse events, on the basis that Tα-1 has shown clinical benefits in patients whose immune functions are severely compromised or ineffective [4].

Direction of studyPopulationReported framing
Tα1 given with a PD-1 inhibitorOne patient with nasopharyngeal carcinomaMultisystem irAEs reported; authors call for vigilance against immune overactivation [2]
Tα1 explored as treatment for irAEsPatients with irAEs secondary to ICIs (registered trial)Rationale is prior clinical benefit in severely compromised immune function [4]

Thymosin Alpha-1 and immunosenescence in aging

Aging is characterised by immune decline attributed mainly to thymic involution, the age-related shrinkage of the thymus gland, which leads to reduced T-cell production, chronic inflammation and increased susceptibility to age-related diseases. Tα1 is described in that review as exhibiting immunomodulatory, anti-inflammatory and antioxidant properties, and as helping restore immune function by stimulating T-cell differentiation, enhancing thymic output, and modulating dendritic cell and macrophage activity [3]. Preclinical and clinical studies cited in the review are said to show that Tα1 can improve vaccine response in the elderly and mitigate immunosenescence [3].

Thymosin Alpha-1 and dendritic cell TLR7 signalling after chemotherapy

Chemotherapy induces cancer cell apoptosis and release of apoptotic bodies that are poorly immunogenic or immunosuppressive, which is described as a major barrier to coadministered or second-line immunotherapies. In that study, circulating levels of Tα-1 were found to be reduced, and the work reports that Tα-1 restores chemotherapy-induced antitumor immunity by chaperoning a microRNA ligand of TLR7 in dendritic cells [9]. This is a mechanistic finding reported in the cited paper; it is not a clinical endpoint.

Thymosin Alpha-1 with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma

A retrospective study set out to validate the efficacy and safety of thymosin α-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma, in patients treated with lenvatinib plus sintilimab at a single hospital in Guangxi Zhuang Autonomous Region from January 20 (date truncated in the evidence block) [10]. The evidence block does not report the outcome measures or results of that retrospective analysis, so no efficacy claim is made here.

Thymosin Alpha-1 with adebrelimab and chemotherapy in resectable esophageal squamous cell carcinoma

A prospective, single-arm, multicentre study conducted in China is enrolling patients with pathologically or cytologically confirmed resectable esophageal squamous cell carcinoma to explore the efficacy and safety of adebrelimab combined with thymalfasin and chemotherapy as neoadjuvant therapy. The study comprises a screening period of no more than 21 days from informed consent to first study drug administration, a treatment period including neoadjuvant therapy and surgery, and a follow-up period comprising safety follow-up and survival follow-up [6].

Thymosin Alpha-1 as adjunctive therapy in recurrent implantation failure

A registered clinical trial is evaluating the safety and efficacy of Thymosin-α1 as an adjunctive immunomodulatory therapy in women with unexplained recurrent implantation failure undergoing IVF/ICSI cycles [7]. The evidence block gives the population and the objective; it does not report results.

Thymosin Alpha-1 in peptide therapy reviews of thyroid and endocrine-immune modulation

A review of peptide therapies in thyroid health notes that thyroid disorders, particularly autoimmune conditions such as Hashimoto's thyroiditis, are frequently associated with persistent systemic symptoms despite biochemical normalisation with standard hormone replacement, which has prompted investigation into adjunctive strategies targeting immune, metabolic and neuroendocrine pathways [11]. Tα1 appears within that broader discussion of peptide therapies rather than as the subject of a dedicated trial in the evidence block.

Thymosin Alpha-1 in combination regimens for soft tissue sarcoma and acute aortic dissection

Two registered studies place Tα1-adjacent immunomodulation inside larger combination or stratification designs. In soft tissue sarcoma, a phase II single-arm study evaluates spatially fractionated radiotherapy combined with a strategy that includes Toripalimab and recombinant human granulocyte-macrophage colony-stimulating factor, asking whether the combination improves clinical prognosis and what adverse events participants encounter [8]. In acute aortic dissection, a prospective multicentre randomised controlled trial of 300 patients assigns participants to subtyping-based precision therapy or to empirical strategies, within a programme that constructs an AI immunoinflammatory subtyping system, on the rationale that immunoinflammatory response drives lesion progression and that current perioperative anti-inflammatory therapies are mostly empirical and poorly targeted [5]. Neither study is a Tα1 monotherapy study, and neither reports results in the evidence block.

Thymosin Alpha-1 in a hybrid fusion drug context

The aging review also refers to the hybrid drug Refnot, described there as a fusion product, in the context of Tα1-related immunomodulation [3]. The evidence block does not provide further detail on that agent, so no additional characterisation is offered here.

If you are reading this for personal health reasons

This material is sold for laboratory research use only, and we do not provide dosing or medical guidance. Nothing on this page is a recommendation for any person to take Thymosin Alpha-1 or any other compound. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp